MedPath

The effect of Quince syrup in pediatric gastroesophageal reflux aged 12 to 48 months

Phase 3
Conditions
Gastro-oesophageal reflux.
Gastro-esophageal reflux disease
Registration Number
IRCT20170501033750N2
Lead Sponsor
Babol University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Patients in the age group of 12 to 48 months.
People with at least 2 times a week with common symptoms of reflux disease (heartburn, regurgitation, vomiting, epigastric pain and appropriate weight loss for at least a month
Those who are newly diagnosed or who have been suffering from reflux, have not taken any medications for at least one month and will want to start their treatment again

Exclusion Criteria

Patients with severe reflux disease (severe onset: symptoms of severe esophagitis, vomiting, life-threatening symptoms such as apnea, pneumonia, esophageal stricture and systemic diseases) due to the need for treatments Another intervention, including surgery or other medications, is withdrawn from the project because of ethical considerations (non-deprivation of the patient and non-risk for the volunteers)
Children with a disease (neurological, cardiac, pulmonary, liver and kidney) or mental retardation
People who have used other herbal remedies during this period
People who need to use chemical drugs during the plan due to the specific disease
People with a history of allergy to herbal medicines

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath